IDH2 and acute myeloid leukemia: It is worth noting that a phase 3 trial comparing enasidenib to conventional care in older patients with R/R AML and the IDH2 mutation failed to meet its primary endpoint of an improved OS, leading to its market withdrawal in Canada [96,97].